Delaware | 001-15925 | 13-3893191 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240 .14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 2.02 | Results of Operations and Financial Condition |
ITEM 9.01 | Financial Statements and Exhibits |
Date: April 25, 2007 | COMMUNITY HEALTH SYSTEMS, INC. | |||||
(Registrant) | ||||||
By: | /s/ Wayne T. Smith
|
|||||
Chairman of the Board, President and Chief Executive Officer |
||||||
(principal executive officer) | ||||||
By: | /s/ W. Larry Cash
|
|||||
W. Larry Cash | ||||||
Executive Vice President, Chief Financial Officer and Director |
||||||
(principal financial officer) | ||||||
By: | /s/ T. Mark Buford
|
|||||
Vice President and Corporate Controller | ||||||
(principal accounting officer) |
2
Exhibit Number | Description | |
99.1
|
Press Release dated April 25, 2007 |
3
Investor Contact: | W. Larry Cash Executive Vice President and Chief Financial Officer (615) 465-7000 |
Three Months Ended | ||||||||
March 31, | ||||||||
2007 | 2006 | |||||||
Net operating revenues |
$ | 1,203,997 | $ | 1,026,562 | ||||
Adjusted EBITDA (a) |
$ | 170,199 | (b) | $ | 158,458 | |||
Income from continuing operations |
$ | 54,324 | $ | 57,254 | ||||
Net income |
$ | 54,324 | $ | 54,038 | ||||
Income from continuing operations
per share-basic |
$ | 0.58 | $ | 0.59 | ||||
Income from continuing operations
per share-diluted |
$ | 0.58 | (b) | $ | 0.58 | |||
Net income per share basic |
$ | 0.58 | $ | 0.56 | ||||
Net income per share diluted |
$ | 0.58 | (b) | $ | 0.55 | |||
Weighted average number of shares
outstanding basic |
93,403 | 96,552 | ||||||
Weighted average number of shares
outstanding diluted |
94,365 | 98,209 | ||||||
Net cash provided by operating activities |
$ | 120,347 | $ | 90,814 |
(Footnotes on next page.) |
(a) | EBITDA consists of income before interest, income taxes, and depreciation and amortization. Adjusted EBITDA is EBITDA adjusted to exclude discontinued operations and minority interest in earnings. The Company has from time to time sold minority interests in certain of its subsidiaries or acquired subsidiaries with existing minority interest ownership positions. The Company believes that it is useful to present adjusted EBITDA because it excludes the portion of EBITDA attributable to these third party interests and clarifies for investors the Companys portion of EBITDA generated by continuing operations. The Company uses adjusted EBITDA as a measure of liquidity. The Company has included this measure because it believes it provides investors with additional information about the Companys ability to incur and service debt and make capital expenditures. Adjusted EBITDA is the basis for a key component in the determination of the Companys compliance with some of the covenants under the Companys senior secured credit facility, as well as to determine the interest rate and commitment fee payable under the senior secured credit facility. | |
Adjusted EBITDA is not a measurement of financial performance or liquidity under generally accepted accounting principles. It should not be considered in isolation or as a substitute for net income, operating income, cash flows from operating, investing or financing activities, or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from adjusted EBITDA are significant components in understanding and evaluating financial performance and liquidity. This calculation of adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. | ||
The following table reconciles adjusted EBITDA, as defined, to net cash provided by operating activities as derived directly from the consolidated financial statements for the three months ended March 31, 2007 and 2006 (in thousands): |
Three Months Ended | ||||||||
March 31, | ||||||||
2007 | 2006 | |||||||
Adjusted EBITDA |
$ | 170,199 | $ | 158,458 | ||||
Interest expense, net |
(30,404 | ) | (21,787 | ) | ||||
Provision for income taxes |
(34,008 | ) | (36,298 | ) | ||||
Loss from operations of hospital sold,
net of taxes |
| (657 | ) | |||||
Depreciation and amortization of
discontinued operations |
| | ||||||
Other non-cash expenses, net |
5,704 | (1,299 | ) | |||||
Net changes in operating assets and liabilities,
net of effects of acquisitions |
8,856 | (7,603 | ) | |||||
Net cash provided by operating activities |
$ | 120,347 | $ | 90,814 | ||||
(b) | Includes additional stock-based compensation expense of approximately $2.7 million, or $0.02 per diluted share, representing an additional incremental year of stock-based compensation expense as no restricted stock or options were granted in 2004. |
Three Months Ended | ||||||||||||||||
March 31, | ||||||||||||||||
2007 | 2006 | |||||||||||||||
Amount | % | Amount | % | |||||||||||||
Net operating revenues |
$ | 1,203,997 | 100.0 | % | $ | 1,026,562 | 100.0 | % | ||||||||
Operating expenses: |
||||||||||||||||
Salaries and benefits |
486,336 | 40.4 | % | 407,668 | 39.7 | % | ||||||||||
Provision for bad debts |
135,699 | 11.3 | % | 107,591 | 10.5 | % | ||||||||||
Supplies |
140,508 | 11.7 | % | 122,820 | 12.0 | % | ||||||||||
Other operating expenses |
245,259 | 20.3 | % | 207,043 | 20.2 | % | ||||||||||
Rent |
25,996 | 2.2 | % | 22,982 | 2.2 | % | ||||||||||
Depreciation and amortization |
51,270 | 4.2 | % | 42,506 | 4.1 | % | ||||||||||
Minority interests in earnings |
193 | 0.0 | % | 613 | 0.1 | % | ||||||||||
Total expenses |
1,085,261 | 90.1 | % | 911,223 | 88.8 | % | ||||||||||
Income from operations |
118,736 | 9.9 | % | 115,339 | 11.2 | % | ||||||||||
Interest expense, net |
30,404 | 2.6 | % | 21,787 | 2.1 | % | ||||||||||
Income from continuing operations
before income taxes |
88,332 | 7.3 | % | 93,552 | 9.1 | % | ||||||||||
Provision for income taxes |
34,008 | 2.8 | % | 36,298 | 3.5 | % | ||||||||||
Income from continuing operations |
54,324 | 4.5 | % | 57,254 | 5.6 | % | ||||||||||
Discontinued
operations, net of taxes: |
||||||||||||||||
Loss from operations |
| | (657 | ) | -0.1 | % | ||||||||||
Loss on sale of hospital |
| | (2,559 | ) | -0.2 | % | ||||||||||
Loss on discontinued operations |
| | (3,216 | ) | -0.3 | % | ||||||||||
Net income |
$ | 54,324 | 4.5 | % | $ | 54,038 | 5.3 | % | ||||||||
Income from continuing operations per share-basic |
$ | 0.58 | $ | 0.59 | ||||||||||||
Income from continuing operations per share-diluted |
$ | 0.58 | $ | 0.58 | ||||||||||||
Net income per share basic |
$ | 0.58 | $ | 0.56 | ||||||||||||
Net income per share diluted |
$ | 0.58 | $ | 0.55 | ||||||||||||
Weighted average number of shares
outstanding: |
||||||||||||||||
Basic |
93,403 | 96,552 | ||||||||||||||
Diluted |
94,365 | 98,209 | ||||||||||||||
Net Income per share calculation: |
||||||||||||||||
Net income |
$ | 54,324 | $ | 54,038 | ||||||||||||
Add Convertible notes interest, net of taxes |
| 135 | ||||||||||||||
Adjusted net income |
$ | 54,324 | $ | 54,173 | ||||||||||||
Weighted average number of shares
outstanding basic |
93,403 | 96,552 | ||||||||||||||
Add effect of dilutive securities: |
||||||||||||||||
Stock awards |
962 | 1,068 | ||||||||||||||
Convertible notes |
| 589 | ||||||||||||||
Weighted average number of shares
outstanding diluted |
94,365 | 98,209 | ||||||||||||||
For the Three Months Ended March 31, | ||||||||||||||||||||||||
Consolidated | Same-Store | |||||||||||||||||||||||
2007 | 2006 | % Change | 2007 | 2006 | % Change | |||||||||||||||||||
Number of hospitals (at end of period) |
77 | 70 | 69 | 69 | ||||||||||||||||||||
Licensed beds (at end of period) |
9,133 | 8,074 | 8,053 | 7,994 | ||||||||||||||||||||
Beds in service (at end of period) |
7,343 | 6,528 | 6,521 | 6,453 | ||||||||||||||||||||
Admissions |
89,024 | 78,966 | 12.7 | % | 79,030 | 78,271 | 1.0 | % | ||||||||||||||||
Adjusted admissions |
163,016 | 143,168 | 13.9 | % | 143,820 | 142,178 | 1.2 | % | ||||||||||||||||
Patient days |
364,180 | 333,249 | 9.3 | % | 326,503 | 330,382 | -1.2 | % | ||||||||||||||||
Average length of stay (days) |
4.1 | 4.2 | 4.1 | 4.2 | ||||||||||||||||||||
Occupancy rate (average beds in service) |
55.1 | % | 57.0 | % | 56.0 | % | 57.2 | % | ||||||||||||||||
Net operating revenues |
$ | 1,203,997 | $ | 1,026,562 | 17.3 | % | $ | 1,079,826 | $ | 1,017,593 | 6.1 | % | ||||||||||||
Net inpatient revenue as a % of
total net operating revenues |
50.4 | % | 50.9 | % | 50.5 | % | 50.9 | % | ||||||||||||||||
Net outpatient revenue as a % of
total net operating revenues |
48.5 | % | 47.8 | % | 48.4 | % | 45.0 | % | ||||||||||||||||
Income from operations |
$ | 118,736 | $ | 115,339 | 2.9 | % | $ | 206,662 | $ | 200,649 | 3.0 | % | ||||||||||||
Income from operations as a
% of net operating revenues |
9.9 | % | 11.2 | % | 19.1 | % | 19.7 | % | ||||||||||||||||
Depreciation and amortization |
$ | 51,270 | $ | 42,506 | $ | 45,783 | $ | 42,139 | ||||||||||||||||
Minority interest in earnings |
$ | 193 | $ | 613 | $ | 193 | $ | 613 | ||||||||||||||||
Liquidity Data: |
||||||||||||||||||||||||
Adjusted EBITDA |
$ | 170,199 | $ | 158,458 | 7.4 | % | ||||||||||||||||||
Adjusted EBITDA as a % of net
operating revenues |
14.1 | % | 15.4 | % | ||||||||||||||||||||
Net cash provided by operating activities |
$ | 120,347 | $ | 90,814 | ||||||||||||||||||||
Net cash provided by operating
activities as
a % of net operating revenue |
10.0 | % | 8.8 | % |
March 31, | December 31, | |||||||
2007 | 2006 | |||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ | 62,878 | $ | 40,566 | ||||
Patient accounts receivable, net of allowance for doubtful accounts of
$497,354
and $478,565 at March 31, 2007 and December 31, 2006, respectively |
817,497 | 773,984 | ||||||
Supplies |
113,315 | 113,320 | ||||||
Deferred income taxes |
13,249 | 13,249 | ||||||
Prepaid expenses and taxes |
35,712 | 32,385 | ||||||
Other current assets |
49,354 | 47,880 | ||||||
Total current assets |
1,092,005 | 1,021,384 | ||||||
Property and equipment |
2,667,923 | 2,630,366 | ||||||
Less accumulated depreciation and amortization |
(682,220 | ) | (643,789 | ) | ||||
Property and equipment, net |
1,985,703 | 1,986,577 | ||||||
Goodwill |
1,332,422 | 1,336,525 | ||||||
Other assets, net |
198,786 | 162,093 | ||||||
Total assets |
$ | 4,608,916 | $ | 4,506,579 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities |
||||||||
Current maturities of long-term debt |
$ | 23,058 | $ | 35,396 | ||||
Accounts payable |
239,889 | 247,747 | ||||||
Current income taxes payable |
25,524 | 7,626 | ||||||
Accrued interest |
11,675 | 7,122 | ||||||
Accrued liabilities |
290,570 | 277,392 | ||||||
Total current liabilities |
590,716 | 575,283 | ||||||
Long-term debt |
1,900,849 | 1,905,781 | ||||||
Deferred income taxes |
141,472 | 141,472 | ||||||
Other long-term liabilities |
195,429 | 160,370 | ||||||
Stockholders equity |
||||||||
Preferred
stock, $.01 par value per share, 100,000,000 shares authorized;
none issued |
| | ||||||
Common stock, $.01 par value per share, 300,000,000 shares authorized;
95,723,518 shares issued and 94,747,969 shares outstanding
at March 31, 2007 and 95,026,494 shares issued and 94,050,945 shares
outstanding at December 31, 2006 |
957 | 950 | ||||||
Additional paid-in capital |
1,202,476 | 1,195,947 | ||||||
Treasury stock, at cost, 975,549 shares at March 31, 2007 and
December 31, 2006 |
(6,678 | ) | (6,678 | ) | ||||
Unearned stock-based compensation |
| | ||||||
Accumulated other comprehensive income |
1,715 | 5,798 | ||||||
Retained earnings |
581,980 | 527,656 | ||||||
Total stockholders equity |
1,780,450 | 1,723,673 | ||||||
Total liabilities and stockholders equity |
$ | 4,608,916 | $ | 4,506,579 | ||||
Three Months Ended | ||||||||
March 31, | ||||||||
2007 | 2006 | |||||||
Cash flows from operating activities |
||||||||
Net income |
$ | 54,324 | $ | 54,038 | ||||
Adjustments to reconcile net income to net cash provided by
operating activities: |
||||||||
Depreciation and amortization |
51,270 | 42,506 | ||||||
Minority interest in earnings |
193 | 613 | ||||||
Stock-based compensation expense |
6,330 | 3,651 | ||||||
Loss on sale of hospital |
| 3,937 | ||||||
Excess tax benefits relating to stock-based compensation |
(758 | ) | (4,360 | ) | ||||
Other non-cash expenses, net |
132 | (590 | ) | |||||
Changes in operating assets and liabilities, net of effects of acquisitions
and divestitures: |
||||||||
Patient accounts receivable |
(33,322 | ) | (42,326 | ) | ||||
Supplies, prepaid expenses and other current assets |
(7,867 | ) | 2,798 | |||||
Accounts payable, accrued liabilities and income taxes |
45,688 | 28,371 | ||||||
Other |
4,357 | 2,176 | ||||||
Net cash provided by operating activities |
120,347 | 90,814 | ||||||
Cash flows from investing activities |
||||||||
Acquisitions of facilities and other related equipment |
(44,039 | ) | (17,448 | ) | ||||
Purchases of property and equipment |
(44,789 | ) | (39,704 | ) | ||||
Disposition of hospital |
| 500 | ||||||
Proceeds from sale of equipment |
134 | 34 | ||||||
Increase in other assets |
(7,051 | ) | (22,425 | ) | ||||
Net cash used in investing activities |
(95,745 | ) | (79,043 | ) | ||||
Cash flows from financing activities |
||||||||
Proceeds from exercise of stock options |
3,311 | 1,919 | ||||||
Excess tax benefits relating to stock-based compensation |
758 | 4,360 | ||||||
Stock buy-back |
| (8,112 | ) | |||||
Deferred financing costs |
(14 | ) | (16 | ) | ||||
Redemption of convertible notes |
| (128 | ) | |||||
Proceeds from minority investors in joint ventures |
1,019 | 3,060 | ||||||
Redemption of minority investments in joint ventures |
(1,253 | ) | (530 | ) | ||||
Distributions to minority investors in joint ventures |
(1,079 | ) | (596 | ) | ||||
Borrowings under credit agreement |
| | ||||||
Repayments of long-term indebtedness |
(5,032 | ) | (3,885 | ) | ||||
Net cash used in financing activities |
(2,290 | ) | (3,928 | ) | ||||
Net change in cash and cash equivalents |
22,312 | 7,843 | ||||||
Cash and cash equivalents at beginning of period |
40,566 | 104,108 | ||||||
Cash and cash equivalents at end of period |
$ | 62,878 | $ | 111,951 | ||||